ライフサイエンスコーパス: contrast-enhanced CT

1 st-enhanced CT and 193 underwent intravenous contrast-enhanced CT.

2 0 patients who underwent portal venous phase contrast-enhanced CT.

3 at routine chest radiography should undergo contrast-enhanced CT.

4 patients with proved HCC underwent biphasic contrast-enhanced CT.

5 s [MPP]), and blood flow measured by dynamic contrast-enhanced CT.

6 edicated CT and abdominopelvic sonography or contrast-enhanced CT.

7 /CT, and in all 7, thrombi were confirmed on contrast-enhanced CT.

8 best coregistered to the fallopian tubes on contrast-enhanced CT.

9 rombus only with additional information from contrast-enhanced CT.

10 ecember 2004, patients underwent intravenous contrast-enhanced CT.

11 4, patients underwent intravenous and rectal contrast-enhanced CT.

12 andard error of the mean]), followed by dual-contrast-enhanced CT (112.4 HU +/- 1.2), iohexol-enhance

13 e the accuracy of combined (18)F-FDG PET and contrast-enhanced CT ((18)F-FDG PET/CT), multidetector C

14 iteria, 223 underwent intravenous and rectal contrast-enhanced CT and 193 underwent intravenous contr

15 as, whose cases constituted the basis for 10 contrast-enhanced CT and 5 MRI studies.

16 Contrast-enhanced CT and MR venography were the most sen

17 Patients underwent contrast-enhanced CT and PET/CT for staging and for resp

18 ET/CT depicts additional sites compared with contrast-enhanced CT and results in upstaging of disease

19 rence between the performance of intravenous contrast-enhanced CT and that of rectal and intravenous

20 Preoperative staging with contrast-enhanced CT and/or MR scans was performed withi

21 g digital subtraction angiography, SPECT/CT, contrast-enhanced CT, and anatomic illustrations.

22 (18)F-FDG PET/CT, contrast-enhanced CT, and nonenhanced CT were performed

23 phy before endovascular stent placement, (b) contrast-enhanced CT angiography 0-3 months after repair

24 by more than 2% on the nonenhanced CT image, contrast-enhanced CT angiography was performed immediate

25 nd dipyridamole (82)Rb perfusion studies and contrast-enhanced CT angiography, using a 64-slice scann

26 A female hound cross underwent whole-body contrast-enhanced CT at a 2-mm slice thickness.

27 All patients underwent routine contrast-enhanced CT at the start and end of preoperativ

28 2 or greater esophageal tumors who underwent contrast-enhanced CT before and after CRT between 2005 a

29 e whether SPECT/CT and additional diagnostic contrast-enhanced CT before radioembolization with (90)Y

30 Adrenal masses detected with contrast-enhanced CT can be characterized as benign or m

31 Intravenous low-osmolar contrast-enhanced CT can safely be used in patients with

32 y) with HL were prospectively evaluated with contrast-enhanced CT (CECT) and PET combined with low-do

33 y) with HL were prospectively evaluated with contrast-enhanced CT (CECT) and PET combined with low-do

34 PET/CT and contrast-enhanced CT (CECT) of the abdomen were performe

35 Contrast-enhanced CT (CECT) using CA4+ reveals significa

36 bstantiates a frequent occurrence of DARs at contrast-enhanced CT compared with that in control subje

37 ; concurrent or subsequent imaging findings (contrast-enhanced CT, contrast-enhanced MRI, sonography,

38 Use of contrast-enhanced CT coronary angiography for detection,

39 ease in size or a 15% decrease in density on contrast-enhanced CT, correlated well in a small trainin

40 Response at interim PET/CT and contrast-enhanced CT could not predict progression-free

41 Archival dynamic contrast-enhanced CT data from 46 patients with colorect

42 ic contrast-enhanced MR imaging (DCEMRI) and contrast-enhanced CT (DCECT) for hepatocellular carcinom

43 Patients were followed up with contrast-enhanced CT every 2-4 months.

44 cion of a thrombus, which was confirmed on a contrast-enhanced CT examination.

45 re (10,121 unenhanced and 10,121 intravenous contrast-enhanced CT examinations in 20,242 patients).

46 erial propagation can be applied to simulate contrast-enhanced CT examinations.

47 Anatomic images were obtained by contrast-enhanced CT, facilitating clear delineation of

48 Visual- and density-based analysis on contrast-enhanced CT failed to differentiate affected fr

49 ilter value, 1.8; slope = -0.0008; P = .003; contrast-enhanced CT: filter value, 1.8; slope = -0.0006

50 36 and .002, respectively) and posttreatment contrast-enhanced CT findings could predict OS (P = .035

51 Posttreatment PET/CT and contrast-enhanced CT findings could predict PFS (P = .03

52 premedication regimen before low-osmolality contrast-enhanced CT for a prior allergic-like or unknow

53 he tumor stage at nonehanced CT increased at contrast-enhanced CT, from IA to IIA (n = 1), IIB to IV

54 ive patients with new-onset dyspnea [four in contrast-enhanced CT group and one in unenhanced CT grou

55 ptom exacerbations within 1 day of CT in the contrast-enhanced CT group compared with the unenhanced

56 The contrast-enhanced CT group was associated with a signifi

57 nd one patient with progressive weakness [in contrast-enhanced CT group]).

58 tients with progressive dyspnea [both in the contrast-enhanced CT group], and one patient with progre

59 The unenhanced and contrast-enhanced CT groups had similar thymectomy rates

60 Intravenous and rectal contrast-enhanced CT had a sensitivity of 92% (95% confi

61 Intravenous contrast-enhanced CT had a sensitivity of 93% (95% CI: 8

62 Patients who underwent contrast-enhanced CT had an increased amount of DNA radi

63 ith corticosteroids beginning 5 hours before contrast-enhanced CT has a breakthrough reaction rate no

64 nderwent ultrasonography (US) and subsequent contrast-enhanced CT if US imaging yielded negative or i

65 quantified from medium to coarse texture on contrast-enhanced CT images showed significant associati

66 ium to coarse texture on both unenhanced and contrast-enhanced CT images showed significant inverse a

67 an index of PD severity) was evaluated using contrast-enhanced CT images while blinded to clinical an

68 Patients underwent FDG-PET/CT and contrast-enhanced CT imaging 8 weeks after completion of

69 Conclusion Adding unenhanced CT to contrast-enhanced CT improved the sensitivity, diagnosti

70 essment models, minimum density analysis and contrast enhanced-CT in the relative subgroups of nodule

71 hanced CT and that of rectal and intravenous contrast-enhanced CT in children suspected of having app

72 e of AKI, dialysis, or death attributable to contrast-enhanced CT in patients with a solitary kidney

73 ents were upstaged by marrow biopsy and 7 by contrast-enhanced CT in the bowel and/or liver or spleen

74 phy (CT) with that of intravenous and rectal contrast-enhanced CT in the evaluation of children suspe

75 Of 7692 women, 1012 (13.2%) underwent contrast-enhanced CT including liver assessment.

76 Either PET/CT or contrast-enhanced CT may be used for response assessment

77 luded in estimating the risk associated with contrast-enhanced CT, may still not fully characterize t

78 correlations were seen between conventional contrast-enhanced CT measurements of fECS and both the I

79 Contrast-enhanced CT measurements of fECS and MMCM uptak

80 Changes in dynamic contrast-enhanced CT measures of tumour relative blood v

81 All lesions at contrast-enhanced CT (n = 5) enhanced.

82 n approximately 1% of patients who underwent contrast-enhanced CT of the chest.

83 ocedures, such as bone scanning and possibly contrast-enhanced CT of the thorax or abdomen-pelvis.

84 Use of both HAP and PVP contrast-enhanced CT optimizes the evaluation of patient

85 erest (VOIs) were delineated on pretreatment contrast-enhanced CT or MR images according to Couinaud

86 SPECT with coregistered contrast-enhanced CT or MR imaging and SPECT/CT images o

87 dard imaging, including routine preoperative contrast-enhanced CT or MRI of the brain, PET of the bra

88 sease sites and two fewer disease sites than contrast-enhanced CT (P = .0003).

89 th-hold T1-weighted MP-GRE imaging than with contrast-enhanced CT, particularly when breath-hold imag

90 was to examine whether (18)F-FDG PET/CT and contrast-enhanced CT performed immediately after percuta

91 that are helpful in evaluating SPNs such as contrast-enhanced CT, PET/CT imaging and also pathologic

92 However, contrast-enhanced CT pulmonary angiography (CTPA) has sh

93 Helical biphasic contrast-enhanced CT represents a considerable improveme

94 Long-term follow-up by way of a contrast-enhanced CT revealed no recanalization of the t

95 Contrast-enhanced CT revealed partial remission in 5, st

96 f preoperative imaging with USG, Doppler and contrast enhanced CT scan can provide correct diagnosis.

97 n of heavy analgesic users to render the non-contrast-enhanced CT scan a sensitive tool to detect ana

98 The abdominal contrast-enhanced CT scan evidenced acute lesions of the

99 thout moving the patient, we performed a non-contrast-enhanced CT scan of the same body region.

100 2 MBq) of (64)Cu-DOTATATE after a diagnostic contrast-enhanced CT scan.

101 l to estimate single-kidney GFR with dynamic contrast-enhanced CT scanning.

102 Contrast-enhanced CT scans in 44 children with pneumonia

103 On (18)F-FDG PET/CT and coregistered contrast-enhanced CT scans of 159 females (age, 16-81 y)

104 ure mass transport properties during routine contrast-enhanced CT scans of individual human PDAC tumo

105 (18)F-FDG PET/CT and contrast-enhanced CT scans were acquired every 3 mo.

106 and coronal) T1-weighted MP-GRE images, and contrast-enhanced CT scans were analyzed.

107 On portal venous phase contrast-enhanced CT scans, attenuation greater than 70

108 On contrast-enhanced CT scans, macroscopic fat (<-30 HU) wa

109 h follow-up gadolinium-enhanced MR images or contrast-enhanced CT scans.

110 Contrast-enhanced CT serves as a useful imaging tool for

111 lignant PNST that arose in a ganglioneuroma, contrast-enhanced CT showed a large, markedly heterogene

112 Baseline PET/CT and contrast-enhanced CT showed concordance in depiction of

113 rospective assessments of 164 unenhanced and contrast-enhanced CT studies from 158 consecutive patien

114 AKI was prevalent in both the unenhanced and contrast-enhanced CT subgroups, and it increased with in

115 Continued growth in the use of contrast-enhanced CT suggests a need for greater awarene

116 lyceride-enhanced CT (126 mg I/kg), and dual-contrast-enhanced CT (triglyceride plus iohexol [425 mg

117 years) with 101 adrenal lesions depicted at contrast-enhanced CT underwent delayed (mean, 9 minutes)

118 Two days later, 6 pigs again underwent contrast-enhanced CT, using a low-radiation-dose approac

119 Results were compared with contrast-enhanced CT, using standardized criteria of mal

120 (82)Rb PET with simultaneous high-resolution contrast-enhanced CT ventriculography, obtained as a byp

121 A total of 20 contrast-enhanced CT volume scans were acquired in 5 swi

122 onset of symptom progression, 2.5 days with contrast-enhanced CT vs 14.0 days with unenhanced CT; P

123 lete response versus no complete response at contrast-enhanced CT was analyzed by using Kaplan-Meier

124 SPECT imaging quantification based on contrast-enhanced CT was reproducible (interexperimenter

125 < .05), and attenuation differences at dual-contrast-enhanced CT were comparable to those at CTAP.

126 sitivity values for lesion detection at dual-contrast-enhanced CT were greater than those at iohexol-

127 Physical examination and contrast-enhanced CT were performed 30 days after comple

128 ARs that were significantly more frequent at contrast-enhanced CT were skin rash (P = .0311), skin re

129 ars) with decreased renal function underwent contrast-enhanced CT with either iso-osmolality iodixano

130 Each patient also underwent non-contrast-enhanced CT within 3 months of the contrast-enh

131 cohort (n = 1425) of patients who underwent contrast-enhanced CT without premedication and who had s